Get informed when a big investor buys or sells
+ Follow-364.33%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Decoy Therapeutics (DCOY) currently reports a ROE of -364.33%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Decoy Therapeutics's ROE history and peer comparisons.
Decoy Therapeutics's ROE of -364.33% is lower than the Healthcare sector average of 13.1%. That is roughly 2880.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Decoy Therapeutics's current -364.33% should be judged against Healthcare norms (sector average: 13.1%) and against DCOY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -364.33%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Decoy Therapeutics, and consider following DCOY for alerts when major investors trade the stock.
Decoy Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -364.33% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DCOY with unrelated industries.